BPC-157 vs GHK-Cu

What is the core difference between BPC-157 and GHK-Cu?

BPC-157 is studied as a systemic tissue and tendon repair peptide, while GHK-Cu is studied as a copper-binding skin and collagen peptide.

BPC-157 is a synthetic peptide derived from a protein found in gastric juice. Most of its published work is preclinical and focuses on healing of tendon, muscle, gut, and other soft tissue in animal models (Sikiric, PMC7096228). GHK-Cu is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) bound to copper. It is best studied for its role in skin, where research reports effects on collagen synthesis and wound-related signaling (Pickart and Margolina, 2018).

The short version: they are both called "repair" peptides, but they target different tissue and rest on different mechanisms.

How does BPC-157 work in published research?

Research reports that BPC-157 promotes healing by supporting new blood-vessel formation through the VEGFR2 and nitric oxide pathway in animal models.

In the Sikiric review of BPC-157 literature (PMC7096228), the peptide is described as accelerating repair of tendon, ligament, muscle, and gastrointestinal tissue in rodents, with angiogenesis (new blood vessel growth) as a repeated theme. The proposed mechanism centers on VEGFR2 activation and nitric oxide signaling, which together support blood flow to injured tissue.

The key limitation is evidence level. The Sikiric body of work is dominated by animal data, and human clinical data for these repair uses remains very limited (Sikiric, PMC7096228). Claims about tendon or gut healing in people extrapolate from animal studies and should be read that way.

How does GHK-Cu work in published research?

GHK-Cu works as a copper-carrying tripeptide that research links to collagen production and skin remodeling.

Pickart and Margolina (2018) describe GHK as a naturally occurring peptide whose levels in the body decline with age. When bound to copper, the GHK-Cu complex is reported in vitro and in animal models to stimulate collagen and other matrix proteins, influence wound-related genes, and support skin remodeling. The copper ion itself is part of the active mechanism, not just a carrier.

As with BPC-157, most of this is laboratory and animal work. Pickart and Margolina (2018) is a mechanistic and review-level source, not a large human efficacy trial, so the human repair evidence is likewise limited.

BPC-157 vs GHK-Cu: decision table

What use case is each peptide studied for?

BPC-157 is studied mostly for deeper soft-tissue and gut repair, while GHK-Cu is studied mostly for skin and collagen.

If the research question is about tendon, muscle, ligament, or gastrointestinal tissue in animal models, BPC-157 is the peptide with that literature (Sikiric, PMC7096228). If the question is about skin structure, collagen density, and matrix remodeling, GHK-Cu is the peptide with that literature (Pickart and Margolina, 2018). They do not fully overlap, so the choice usually follows the tissue in question rather than a head-to-head "which is stronger" comparison.

What are the reported dosing ranges in the research?

Published studies describe dose ranges in animals and in vitro, not personal dosing instructions for people.

Because both compounds are dominated by preclinical work, the literature does not establish a validated human dose for the repair uses discussed here. The Sikiric review (PMC7096228) reports BPC-157 doses in animal models rather than clinician-set human protocols. Pickart and Margolina (2018) describe GHK-Cu concentrations in cell and animal systems and in topical contexts, again not as a human prescription.

Any personal dose, route, or timing is a decision for a qualified clinician who can review your full situation. This page does not recommend a dose.

Which has stronger human evidence?

Neither BPC-157 nor GHK-Cu has strong, large-scale completed human efficacy trials for the repair uses covered here.

Both sit on preclinical foundations. BPC-157's human data is described as very limited (Sikiric, PMC7096228), and GHK-Cu's clinical picture rests on review and mechanistic sources rather than large trials (Pickart and Margolina, 2018). When comparing them, the honest statement is that both need more human research, and confidence in either should be scaled to that.